



FY2023 Q1
Financial Results



Revenue

¥1,058.6_B

+3.7% growth at CER

Core Operating Profit

¥326.3B

-2.0% change at Constant Exchange Rate (CER) reflects product mix and investment in R&D and Data & Technology

Core Operating Profit Margin

30.8%

Reported Operating Profit

¥168.6B

+12.0% growth driven by Growth & Launch Products and currency effects



Core EPS

¥150

+0.3% at CER

Reported EPS

¥58

-15.4% change impacted by one-time gain in Finance
Income in FY2022 Q1



Our extensive portfolio of Growth & Launch Products continued to drive growth.

40%

Share of Total Revenue

+16.2%

Growth at CER





Core Revenue

¥3,840.0B

Core Operating Profit

¥1,015.0B

Core EPS

¥434

Core operating profit expected to exceed ¥1tn despite loss of exclusivity and coronavirus vaccines impact

Management Guidance at CER

Core Revenue

Low-single-digit
% decline

Core Operating Profit

Low-10s
% decline

Core EPS

Low-20s
% decline

Forecasted annual
dividend increase to

¥188

Per share annually

Adopted progressive dividend policy of
increasing or maintaining dividend
each year



This presentation contains forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda's FY2023 Q1 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.

Core Revenue, Core Operating Profit, Core Operating Profit Margin, Core EPS, CER % Change, Net Debt, Adjusted EBITDA, and Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda's FY2023 Q1 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>) for further information about Takeda's Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.



